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Background. Quantiﬁcation of cytomegalovirus (CMV) load is central to the management of CMV infections in
immunocompromised patients, but quantitative results currently differ signiﬁcantly across methods and laboratories.
Methods. The COBAS AmpliPrep/COBAS TaqMan CMV Test (CAP/CTM CMV test), developed using the ﬁrst
World Health Organization CMV standard in the calibration process, was compared to local assays used by 5 labora-
tories at transplant centers in the United States and Europe. Blinded plasma panels (n = 90) spiked with 2.18–6.7
log10 copies/mL and clinical plasma samples from immunocompromised patients (n = 660) were tested.
Results. Observed mean panel member concentrations by site and 95% conﬁdence intervals (CIs) of the data
combined across sites were narrower for CAP/CTM CMV test compared with local assays. The 95% CI in log10
copies/mL of the combined data per panel member for CAP/CTM CMV test vs comparator assays was .17 vs 1.5 at
2.18 log10 copies/mL; .14 vs .52 at 2.74 log10 copies/mL; .16 vs .6 at 3.3 log10 copies/mL; .2 vs 1.11 at 4.3 log10 copies/
mL; .21 vs 1.13 at 4.7 log10 copies/mL; and .18 vs 1.4 at 6.7 log10 copies/mL. In clinical specimens, constant and
variable quantiﬁcation differences between the CAP/CTM CMV test and comparator assays were observed.
Conclusions. High interlaboratory agreement and precision of CAP/CTM CMV test results across 5 different
laboratories over 4 orders of magnitude suggest that this assay could be valuable in prospective studies identifying
clinical viral load thresholds for CMV treatment.
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Human cytomegalovirus (CMV) infection causes signif-
icant morbidity and mortality in the posttransplant
period of both solid organ transplant (SOT) and hema-
topoietic stem cell transplant (HSCT) recipients [1–5].
Seronegative recipients of transplants from seropositive
donors are infected by CMV transmitted through the
transplanted organ or inadvertently through CMV-
positive blood products [1–5]. In CMV-seropositive re-
cipients, reactivation of latent CMV occurs when
CMV-speciﬁc immune control is impaired by immuno-
suppressive drugs and T-cell–depleting therapies [1–5].
The diagnosis of CMV replication and disease in
SOT and HSCT recipients can be made using different
laboratory methods, including histology, pp65 antige-
nemia, or CMV DNA by quantitative nucleic acid
testing (QNAT) [1–5]. Culture methods of body ﬂuids
and tissue samples are generally slow and are not
quantitative [4]. The pp65 antigenemia test is rapid (1
day time-to-result) but less sensitive than QNAT and
often difﬁcult to perform on severely neutropenic
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patients [1–7]. CMV QNAT, based most commonly on poly-
merase chain reaction (PCR), has largely replaced convention-
al methods owing to better overall performance, and clinical
guidelines now recommend the use of these assays for CMV
load monitoring in SOT and HSCT recipients to prevent or to
manage CMV replication and disease [4, 5, 7, 8].
One central issue that has emerged with the use of different
CMV PCR tests is the signiﬁcant interassay quantiﬁcation vari-
ability, as demonstrated in multicenter studies with standard-
ized panels [9, 10]. This lack of assay agreement complicates the
management of individual patients who may have testing per-
formed in different laboratories and it has hampered the estab-
lishment of broadly applicable quantitative cutoff values that
can be used in clinical decision making, potentially negatively
impacting the management and long-term outcome of patients
at risk of the direct and indirect effects of CMV replication [1,
4, 5]. Therefore, in the clinical management of CMV after
transplantation, there is a signiﬁcant unmet medical need for
the development of standardized nucleic acid tests that deliver
comparable quantitative data across different laboratories.
The ﬁrst international standard for CMV QNAT has recently
been established by the World Health Organization (WHO)
Expert Committee on Biological Standardization [11]. This
CMV standard should help to improve interassay agreement.
However, assay-speciﬁc variability is still expected owing to un-
derlying differences in test constituents, including varying
nucleic acid extraction methods, target-speciﬁc ampliﬁcation ef-
ﬁciencies, assay biochemistries, and operator-dependent vari-
ability. As recently suggested [12], these residual quantiﬁcation
disparities could be solved through the widespread availability
of commercial PCR tests that encompass all assay steps (nucleic
acid preparation, reaction setup, calibration, ampliﬁcation, and
detection) and demonstrate reliable interlaboratory quantiﬁca-
tion as deﬁned by agreement and precision. Here, we report the
results of a multicenter international study designed to deter-
mine the comparability of quantitative data and precision of a
new, fully automated, Food and Drug Administration–approved
CMV QNAT (COBAS AmpliPrep/COBAS TaqMan CMV Test
[CAP/CTM CMV test]) using a blinded panel across diverse
laboratories and to compare these 2 parameters among the 5
different assays currently used in these laboratories. Agreement
between the CAP/CTM CMV test and the diverse in-house
quantiﬁcation assays was also deﬁned using clinical plasma
specimens from immunocompromised individuals.
METHODS
CAP/CTM CMV Test Colinearity to the First WHO CMV
International Standard
The CAP/CTM CMV test (Roche Molecular Systems, Inc
[RMS], Branchburg, New Jersey) analytical performance
characteristics, including traceability to the ﬁrst WHO CMV
international standard for nucleic acid ampliﬁcation tech-
niques (NIBSC 09/162) were described previously [13].
In brief, the CAP/CTM CMV test uses primers and probes
targeting a conserved region of the CMV genome (UL54,
virus encoded DNA polymerase) and has a linear quantiﬁca-
tion range from 150 to 10 000 000 (2.18–7.0 log10) copies/mL
representing 137 and 9 100 000 (2.14–6.96 log10) IU/mL, re-
spectively (1 copy = 0.91 IU). Several standards and control
specimens were used during the development of the test to
achieve traceability to the ﬁrst WHO CMV international stan-
dard as recommended by the Clinical and Laboratory Stan-
dards Institute guidelines [14]. The standards included the
WHO CMV standard, RMS CMV secondary standard, RMS
CMV secondary standard source material (CMV strain
AD169), and RMS CMV calibration panel (Lambda CMA1.2).
The standards, the calibration panel, and an independent
CMV clinical specimen were tested at similar levels to deter-
mine whether colinearity to the WHO CMV standard
was achieved. Assessment of colinearity was performed to
demonstrate that the WHO standard was commutable
at any given titer throughout the measuring range and to
thereby ensure traceability. The concentration range tested
for the WHO CMV standard was from 500 IU/mL to 50 000
IU/mL (2.70–5.70 log10 IU/mL), the RMS CMV secondary
standard source material was tested from 500 IU/mL to
10 million IU/mL (2.70–7.00 log10 IU/mL), the RMS CMV cali-
bration panel was tested from 523 to 9.3 million IU/mL (2.72–
6.97 log10 IU/mL), and the independent CMV clinical specimen
was tested from 500 IU/mL to 22 686 IU/mL (2.70–4.36 log10
IU/mL). The standard and control specimens were demon-
strated to be colinearly distributed to the WHO material
across the linear range of the CAP/CTM CMV test (Supple-
mentary Figure 1).
CMV DNA Quantiﬁcation Tests
CMV DNA quantiﬁcation with the CAP/CTM CMV test was
compared to in-house tests of record at each of 5 academic
centers including The John Hopkins Hospital (site 2, real-time
PCR based on Artus reagents [Qiagen, Germantown, Mary-
land]), Hospital Universitario de la Princesa (site 3, Afﬁgene
real-time PCR test [Cepheid, Sunnyvale, California]) Universi-
ty of Basel (site 4, user-deﬁned real-time PCR [UL111a gene
target]), Stanford University (site 5, COBAS AMPLICOR
MONITOR CMV test [RMS]), and Helsinki University Hos-
pital (site 6, user-deﬁned real-time PCR [pp65 gene target]).
The analytical performance characteristics for commercial and
laboratory-developed quantitative PCR assays have been de-
scribed previously [15–19].
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Comparability and Reproducibility of the CAP/CTM CMV Test
and 5 Quantitative PCR Assays
Comparability and reproducibility of the CAP/CTM CMV test
was studied in comparison with 3 assays based on commercial
reagents, and 2 tests that use laboratory-developed primers
and probes using a panel prepared from a well-characterized
CMV cultured virus stock (strain AD-169, titer assigned by
the COBAS AMPLICOR CMV MONITOR Test). The panel
consisted of 6 dilutions; 150, 550, 2000, 20 000, 50 000, and
5 000 000 copies/mL (2.18, 2.74, 3.3, 4.3, 4.7, and 6.7 log10
copies/mL, respectively). These dilutions covered the dynamic
range of the CAP/CTM CMV test and represent relevant clin-
ical viral load thresholds [1–7, 13]. The prepared virus stock
dilutions were further diluted in CMV-negative human ethyl-
enediaminetetraacetic acid plasma. Each site tested 15 replicates
of each panel member with CAP/CTM CMV and in-house
tests except site 2 (15 replicates by CAP/CTM CMV/12 repli-
cates of in-house test). The CMV DNA panel was prepared at
RMS and shipped to the study sites labeled with coded sample
identiﬁcation numbers to ensure that the site study staff was
blinded to the CMV DNA concentration of each panel
member. These experiments were designed in accordance with
guidelines for establishing analytical performance characteris-
tics of QNATs [20].
Quantitative Agreement Between CAP/CTM CMV Test and 5
Quantitative PCR Assays Using Clinical Specimens From
Immunocompromised Patients
Agreement between CAP/CTM CMV test and the 5 quantita-
tive PCR assays described above was investigated with plasma
samples collected at the study sites from immunocompro-
mised patients monitored for CMV replication and disease.
Specimens were assayed only at the site that performed origi-
nal testing. In addition, 403 samples from 135 HSCT recipi-
ents participating in the maribavir prophylaxis for prevention
of CMV phase 3 trial (NCT00411645) were provided by Viro-
Pharma, Inc, to the study sites for PCR testing [21]. Only pa-
tients with plasma samples with a volume >600 μL were
included in this analysis, and due to volume requirements for
in-house testing, site 2 did not quantify samples from the
maribavir prophylaxis trial. Plasma samples from the mariba-
vir prevention trial were randomly distributed to the other 4
study sites. Institutional review board approval was obtained
at each institution for this study.
Statistical Analysis
The precision of log10-transformed valid test results within the
linear range of each assay was estimated at each expected log10
CMV DNA concentration. The log-normal mean and log-
normal coefﬁcient of variation (%) and 95% conﬁdence inter-
vals (CIs) (including the lower and upper conﬁdence limits) for
total variance were calculated using the linear mixed effect
model with site and day/run, and within-run as random effects.
Deming regression analysis of the viral load results for each
local assay vs the CAP/CTM CMV test was performed to eval-
uate the correlation between the assays overall and by study
site. All the statistical analyses were performed using the stat-
istical software SAS version 9.2.
Figure 1. Comparability of quantitative data across laboratory sites. A
dilution series of cytomegalovirus (CMV) AD-169 was prepared using
cytomegalovirus-seronegative plasma. Geometric means of tested repli-
cates are plotted. Numerical ranges indicate 95% conﬁdence intervals of
the means of each panel member at each site. A, COBAS AmpliPrep/
COBAS TaqMan CMV data. Dashed line indicates assay lower limit of
quantiﬁcation. B, Data from 5 comparator polymerase chain reaction
assays. Abbreviations: CAP/CTM CMV, COBAS AmpliPrep/COBAS
TaqMan CMV Test; CMV, cytomegalovirus.
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RESULTS
Comparability and Reproducibility of Quantitative PCR Assays
With a Standardized CMV DNA Panel
To determine comparability of quantitative data obtained with
CAP/CTM CMV test across laboratories vs participating
centers’ PCR assays, plasma panels spiked with CMV strain
AD-169 from 2.18–6.7 log10 copies/mL were tested at the 5
study sites. The level of quantitative agreement was high for
the CAP/CTM CMV test across the different laboratories as
demonstrated by a smaller range of mean concentrations of
panel members by site and narrower CIs of the combined data
per panel member compared to in-house PCR test in clinical
use at the study sites (Figure 1). For CAP/CTM CMV, the
greatest quantitative variability was observed for the lowest
concentration panel member (2.18 log10 copies/mL, the test’s
lower limit of quantiﬁcation); all replicates were detected, but
62/75 (83%) could not be quantiﬁed. This panel member was
also variably detected by each comparator PCR assay. The
AMPLICOR assay (site 5) failed to detect 11/15 replicates
(73%), whereas the Afﬁgene CMV trender test (site 3) was
able to quantify 15/15 replicates. Overall, of 72 valid compara-
tor PCR assay results, 12 replicates were not detected, 22 were
below the lower limit of quantiﬁcation, and 38 (53%) were
quantiﬁed (Supplementary Table 1).
Data from experiments with the spiked plasma panel were
also used to compare the precision of the CAP/CTM CMV
test to the in-house PCR assays used by the study sites. The
standard deviation was <0.2 log10 copies/mL for most panel
members across the different sites performing the CAP/CTM
CMV test, with 2 exceptions (2.18 and 6.7 log10 copies/mL for
site 2 and site 6 tests, respectively, Figure 2). Similar reproduc-
ibility was observed for the AMPLICOR test (site 5), CMV
real-time PCR (UL111a PCR, site 4) and real-time PCR (pp65
PCR, site 6) in-house assays. The Artus CMV PCR (site 2)
and Afﬁgene CMV (site 3) trender tests demonstrated greater
imprecision (standard deviations >0.2 log10 copies/mL for
multiple panel members). Coefﬁcients of variation demon-
strated similar trends (Supplementary Figure 2).
Quantitative Agreement Between CAP/CTM CMV Test and 5
Quantitative PCR Assays Using Clinical Specimens From
Immunocompromised Patients
Trends in quantitative disagreement between the CAP/CTM
CMV test and study sites’ PCR assays were deﬁned by com-
paring viral loads obtained by the 2 tests on individual plasma
samples from immuncompromised patients. HSCT recipients
comprised 67% (267/396) of the patients studied; these indi-
viduals contributed 80% and 76% of the total number of
samples and valid PCR test results, respectively (Table 1). Two
patterns of disparity were observed (Figure 3). CAP/CTM
CMV test yielded lower values than 3 in-house tests (sites 2, 4,
and 6) throughout the measuring range. Bland-Altman analy-
sis demonstrated this constant bias (least squares regression
slope absolute value <.1, with nonsigniﬁcant P value). Addi-
tionally, for in-house assays at sites 3 and 5, the difference in
Figure 2. Reproducibility of quantitative data across laboratory sites.
Standard deviations of replicates from cytomegalovirus (CMV) AD-169
dilution series are plotted. A, COBAS AmpliPrep/COBAS TaqMan CMV
Test precision by study site. Quantiﬁable replicates at 2.18log10 copies/
mL: site 2, n = 2; site 3, n = 0; site 4, n = 6; site 5, n = 1; site 6, n = 4.
Standard deviations at 2.18log10 copies/mL were not calculated for sites
3 and 5. At 2.74log10 copies/mL, all replicates were quantiﬁable at all
sites except site 6 (11/15 quantiﬁable). B, Precision for the 5 comparator
polymerase chain reaction assays. Replicates of each panel member
tested at site 2, n = 12; at sites 3–6, n = 15. Quantiﬁable replicates at
2.18log10 copies/mL: site 2, n = 2; site 3, n = 15; site 4, n = 11; site 5,
n = 0; site 6, n = 10. Standard deviation at 2.18log10 copies/mL was not
calculated for site 3. At 2.74log10 copies/mL, all replicates were quantiﬁ-
able at all sites except site 4 (0/15 quantiﬁable) and site 5 (9/15 quanti-
ﬁable). Abbreviation: CAP/CTM CMV, COBAS AmpliPrep/COBAS TaqMan
CMV Test.
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quantiﬁcation compared to the CAP/CTM CMV test varied
throughout the measuring range. Bland-Altman analysis
further demonstrated this proportional bias (least squares re-
gression slope absolute value >.1, with signiﬁcant P value,
Figure 3).
DISCUSSION
The data from this multicenter international study demon-
strate that the CAP/CTM CMV test performs consistently
across laboratories, from the perspective of quantitative agree-
ment and reproducibility. Furthermore, the ﬁnding of constant
and variable quantiﬁcation differences among PCR assays cur-
rently used at the participating centers compared with the
CAP/CTM CMV test underscores the challenges in achieving
a general quantitative standardization. Constant bias between
different assays likely reﬂects the use of different calibrators in
assays that are otherwise functionally similar. In these instanc-
es, interassay agreement may improve with adoption of a cali-
brator based on the international standard; alternatively, a
conversion factor can be applied to normalize data if the use
of a different calibrator is not feasible. These fairly easy adjust-
ments are unlikely to improve agreement between assays
whose functionality is sufﬁciently different to result in variable
quantiﬁcation differences throughout the measuring range.
For these assays (with variable quantiﬁcation), assay traceabili-
ty to the international standard alone will not adequately
correct for these types of differences. Instead, these assays
must also demonstrate colinearity to the international
standard throughout the assay measuring range. Ideally, this
approach (to calibrate and establish colinearity to the reference
material, eg, the ﬁrst WHO CMV international standard)
Figure 3. Agreement in cytomegalovirus (CMV) DNA load measurement
between the COBAS AmpliPrep/COBAS TaqMan CMV Test (CAP/CTM
CMV) and 5 comparator polymerase chain reaction (PCR) assays in plasma
samples from immunocompromised individuals. Left-hand panels, agree-
ment plots with Deming regression lines; dashed line indicates 100%
agreement level. Right-hand panels, Bland-Altman plots (difference in
quantiﬁcation between the CAP/CTM CMV test and comparator PCR
assays vs mean of the 2 measurements). Solid line, least squares regres-
sion; dashed lines, mean differences of +0.5/0/−0.5 log10 copies/mL. Ab-
breviation: CAP/CTM CMV, COBAS AmpliPrep/COBAS TaqMan CMV Test.
Table 1. Patient Populations and Number of Samples Used in
the Reproducibility Comparison of COBAS AmpliPrep/COBAS








Solid organ transplant recipients
(n = 107)
107 71
Hematopoietic stem cell transplant
recipients (n = 267)
531 286




Abbreviation: HIV, human immunodeficiency virus.
a Only samples with paired results within the linear range of the polymerase
chain reaction assays were included in the comparison analysis.
b Other immunocompromised patients included subjects diagnosed with
hematologic malignancies (n = 9) or autoimmune diseases (n = 4) receiving
immunosuppressive therapy.
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should be used whenever samples are evaluated in patients
who are monitored for CMV DNA as part of the management
of SOT and HSCT recipients.
Monitoring CMV DNA has become critical for the early
identiﬁcation of viral replication for preventing progression to
disease in the posttransplant period, and for monitoring the
response to antiviral treatment in patients with CMV replica-
tion and disease. In SOT, universal prophylaxis and preemp-
tive treatment approaches are both used to prevent CMV
disease [1, 2, 4, 5]. Although both approaches are currently
viewed as equivalent, the advantages of prophylaxis are pre-
vention of replication and disease in the immediate posttrans-
plant period and elimination of the need for viral load
monitoring during prophylaxis, particularly for the high-risk,
CMV-seropositive donor/CMV-seronegative recipient SOT.
However adverse events associated with prolonged antiviral
drug administration have limited the utility of this approach
in some patients. Also, viral load monitoring may still be
useful in some patients in whom drug-resistant viruses are
suspected to emerge when treated with lower antiviral doses
in an attempt to mitigate drug side effects. Finally, the onset
of late CMV disease has been observed in up to 29% of SOT
recipients after prophylaxis cessation [1, 2, 4].
Viral load monitoring is the key feature of preemptive
therapy. In this alternate approach, antiviral therapy is initiat-
ed before the onset of CMV disease when viral load measure-
ments reach a predictive threshold. Advantages of preemptive
therapy include a smaller proportion of treated patients, short-
ened therapeutic duration, lowered costs associated with post-
transplant medications, and reduced occurrence of drug
toxicity (primarily bone marrow suppression). Avoidance of
marrow suppression is the major rationale for the use of pre-
emptive strategies in allogeneic HSCT in the preengraftment
period. Disadvantages of the preemptive antiviral strategy
include risk of disease prior to treatment initiation in individ-
uals with fast replication, indirect effects of CMV replication
(in the absence of disease) on allograft survival and mortality,
and laboratory costs due to more frequent viral load monitor-
ing. Perhaps one of the most signiﬁcant drawbacks to this ap-
proach is the lack of generally established quantitative cutoffs
that are predictive of CMV disease in recipients of different
allografts due in large part to the lack of standardized quanti-
ﬁcation assays that perform comparably across laboratories.
The lack of standardized CMV load assays has also compli-
cated CMV management in other ways. For individual pa-
tients, quantiﬁcation disparities across laboratories dictate that
a single laboratory should be used for viral load testing, so
that results can be accurately interpreted. In addition, al-
though higher viral loads have been shown to correlate with an
increased risk of disease in SOT and HSCT patients [1, 4, 5],
the lack of standardization has hampered the development of
discrete, globally applicable, quantitative predictors of active
disease, and other cutoffs that can be used to determine
relapse risk and adequate treatment duration [12]. Currently,
the burden of deﬁning these cutoffs is placed on individual
laboratories, and as a result, clinically relevant values still vary
from center to center.
The implementation of an international standard and the
availability of commercial QNATs with broad interlaboratory
agreement that are traceable and colinear to the ﬁrst WHO
CMV international standard represent a much-needed ad-
vancement. As demonstrated here for CAP/CTM CMV,
precise, accurate, and standardized results should allow the
design of multicenter studies to delineate testing algorithms,
including quantitative cutoffs and testing frequencies that
enhance clinical outcomes of CMV infections in HSCT and
SOT patients. In turn, these data can be used as the basis for
management guidelines that should signiﬁcantly clarify deci-
sion making for clinicians and improve infection outcomes in
at-risk patients.
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